Proactive TDM Versus Standard Use of Biologics in Psoriasis
Recruiting · NCT06398106 · Interventional (participants receive a specific treatment) · Lead sponsor: University Hospital, Ghent
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Biologics are effective agents for the treatment of psoriasis. The newest generation of biologics block interleukin 17 and 23. Physicians always prescribe these drugs in a fixed dose, but this may lead to under- and overdosing in some patients. Underdosing may lead to inadequate response or loss of response over time. Overdosage, on the other hand, can lead to higher risk of side effects and higher costs for the healthcare system. In daily clinical practice, physicians often tackle this real-world issue by blind trial- and- error dose modifications or switching to another biologic. In this study, we want to rationalize these dose modifications and optimize dosing based on the drug concentrations, measured in the blood of the patient (i.e. therapeutic drug monitoring). Depending on the drug concentration, the interval between injections will be lengthened or shortened with the aim to reach the required drug concentration to reach the best clinical result. The trial will be conducted in 14 Belgian hospitals where patients will be divided into 2 study groups: a group that will be advised on the dosing scheme of their biologic based on the measured drug concentration and a group that continues dosing as in daily clinical practice. We will monitor if the clinical response and quality of life remains stable. With this study, we will track drug concentrations as we believe that they can guide dosing of biologics and we hope to achieve better safety, lower healthcare expenses and higher patients' treatment satisfaction while striving for the best clinical response.
Who can take part
Inclusion criteria
- Adults; aged 18 years or older
- Documented diagnosis of psoriasis (predominantly type vulgaris; based on clinical diagnosis) by an accredited dermatologist
- Patients must be currently treated with secukinumab, ixekizumab or guselkumab ≥ 6 months according to the standard dosing scheme.
- The subject signs and dates a written informed consent form and any required privacy authorization prior to the initiation of any study procedures
Exclusion criteria
- Another indication than plaque psoriasis as the main indication for biologic use (e.g. receives biologic for rheumatoid arthritis as the main indication)
- Concomitant use of systemic immunosuppressants other than methotrexate or acitretin (e.g. prednisone, cyclosporine etc)
- Severe comorbidities with short life-expectancy (e.g. metastasized tumour) or uncontrolled PsA at inclusion/baseline
- Presumed inability to follow the study protocol
- Active pregnancy wish
Where it is running
15 locations listed.
- AZ Sint-Jan - Bruges, Belgium
- CHU Saint-Pierre - Brussels, Belgium
- UCL Saint-Luc - Brussels, Belgium
- ULB Erasme - Brussels, Belgium
- UZ Brussel - Brussels, Belgium
- Grand Hôpital de Charleroi - Charleroi, Belgium
- AZ Alma - Eeklo, Belgium
- Dermatologiepraktijk huidziekten Geel - Geel, Belgium
- AZ Maria Middelares - Ghent, Belgium
- UZ Gent - Ghent, Belgium
- Clinique André Renard - Herstal, Belgium
- Dermatologie Handelskaai - Kortrijk, Belgium
- UZ Leuven - Leuven, Belgium
- CHU Liège - Liège, Belgium
- Dermatologie Maldegem - Maldegem, Belgium